According to Álvaro Hidalgo, director of the Weber Foundation, between 2000 and 2024 medicines have achieved an increase of 30% in the life expectancy of cancer patients. Also an increase of 40% in longevity – and 68% in mobility – in the case of multiple sclerosis. They save health costs (300,000 euros per patient in hemophilia), reduce informal care and increase productivity. Plus a series of intangible benefits in which María José Sánchez, scientific director of the Biosanitary Research Institute of Granada (IBS.GRANADA) and professor at the Andalusian School of Public Health. If Sanchez alluded to social impact and equitable and democratic access to the trials, Andrés Mayor, President of Action Vision Spain, claimed the patient's figure, formed and informed, participant in his process: “We have a lot to say from the moment in which the clinical trial is designed; We are part of the solution. ”Sánchez defended that the sustainable financing of the system goes through more clinical research units. Nuria Mas, professor of the Department of Economy of the IESE and head of the Jaime Grego Chair of Global Healthcare Management, advocated different financing formulas to sustain clinical investigations. Perhaps Venture Capital, which considers adequate to support more risk initiatives, which, in the long run, will mean savings. «They are paid alone, but not now, but later,» he said. The expert detects inefficiencies and a basic problem: «coffee for all», which is renie. “According to the Draghi report, public R&D spending from the United States and Europe is no different; The difference is that the first is used to concrete projects that have indications that they can work well while the second distributes it between countries that distribute it between projects, ”he explained, more information about this context, he said that the science of data and artificial intelligence (AI) could come to give a hand to the old continent. «Health data is much better in Spain, which is a system, than in the United States, where it is fragmented, or that in China, where there is no historical,» he argued. “Advances in drug-genomic allow personalized therapies with an efficacy 2.3 times higher than traditional ones; The use of AI allows to identify candidates for gene therapies with a 92% precision, and that reduces almost 220 million euros the development and cost of clinical trials, ”said Hidalgo. That said, he placed the challenge on how to value advanced therapies, how to finance them and position them in the market. For this, it is important that the entire system be prepared, for example, at an early diagnosis. Here he highlighted the importance of giving early and agile access to these therapies, remembering that, in rare diseases, late diagnosis costs 23,000 euros per patient.
Retain research talent
Sánchez advocated the cooking of researchers with AI, human intelligence and digital health systems. His allegation for collaboration and joint work also extended researchers with the health system. At this point he highlighted the importance of attracting and retaining research talent. He asked to put innovation not only at the service of clinical trials but also of research, which can benefit from the great data. «We have records of diseases and large population bases with real -life data,» he said. For this, he claimed, once again, the interoperability of health systems between the autonomous communities. He also called to take advantage of the technology applied to health data spaces to prevent, in addition to diagnosing and treating. According to their recommendation, early prevention and diagnosis must go hand in hand to identify subgroups at high risk of suffering a certain disease. «Clinical research is an investment in health, well -being, economy and future,» Sanchez contributed as a final conclusion.
